Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 153

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 153
---
 in active clinical development, it demonstrates a powerful synergistic effect. This versatility suggests significant market expansion potential as it could enhance the efficacy of various immune checkpoint inhibitors across multiple indications.

Figure 4: Second generation anti-CD47 monoclonal antibodies leading immuno-oncology drug development targeting innate immunity

<div align='center'>99</div>

DIRECTORS AND EXECUTIVE OFFICERS Executive Officers and Directors Our directors and executive officers are as follows:

| Name                           |   | Age |   | Position                             |
| Chris Kim                      | ​ |  65 | ​ | Chief Executive Officer and Director |
| Scott Dam                      | ​ |  46 | ​ | Chief Financial Officer              |
| Byong C. Yoo, PhD              | ​ |  53 | ​ | Chief Science Officer                |
| Sang-jin Daniel Lee, PhD       | ​ |  57 | ​ | Head of Research & Development       |
| Beom K. Choi                   | ​ |  53 | ​ | Chief Technology Officer             |
| Eun Sook Lee, MD, PhD(1)(2)(3) | ​ |  62 | ​ | Independent Director                 |
| Nicholas Fernandez(1)(2)(3)    | ​ |  40 | ​ | Independent Director                 |
| Ji Yeon Baek(1)(2)(3)          | ​ |  53 | ​ | Independent Director                 |

| (1) | Member of the Audit Committee. |

| (2) | Member of the Nominating and Corporate Governance Committee. |

| (3) | Member of the Compensation Committee. |

Executive Officers Mr. Chris Kim, JD, LLM —Chief Executive Officer Mr. Chris Kim has been Liminatus Pharma, LLC’s Chief Executive Officer and Managing Member since its founding in May 2018 and has been the Chief Executive Officer and Director of Liminatus Pharma, Inc. since November 23, 2022. From December 2016 to the present, he has also served as Chief Executive Officer of Viral Gene, Inc., Philadelphia, PA. From January 2007 to October 2017, he was Counsel for DeHeng Law Office NY, the largest law firm in China. Mr. Kim has over 30 years of experience in intellectual property law including patent, trademark, copyright, trade secret, unfair competition, and other related areas. Mr. Kim is a graduate of University of Pennsylvania Law School, LLM, SJD (C),